FIELD: medicine.
SUBSTANCE: present invention relates to medicine, namely, to oncology, and relates to combined treatment of non-small cell lung cancer IB-III stage. Treatment is carried out by introduction of carboplatin in combination with one of the following cytotoxic drugs: gemcitobin, irinotecan, vinorelbine doxorubicin and paclitaxel. Choice of a specific cytotoxic is carried out taking into account the level of expression of monoresistant genes RRM1, TYMS, ABCC5, BRCA1, ERCC1, TOP1, TOP2a, TUBB3 in certain ratios.
EFFECT: this provides higher effectiveness of treatment and reduction in side effects due to personified approach to the prescription of chemotherapy.
1 cl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR COMBINED TREATMENT OF NON-SMALL CELL LUNG CANCER IB-III STAGE USING PERSONALIZED PERIOPERATIVE CHEMOTHERAPY | 2019 |
|
RU2706718C1 |
METHOD FOR PERSONALIZED COMBINED TREATMENT OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER STAGE II-III | 2022 |
|
RU2784958C1 |
METHOD OF COMBINATION TREATMENT OF NON-SMALL CELL LUNG CANCER STAGE 1B-111 WITH CUSTOMIZATION OF ADJUVANT CHEMOTHERAPY | 2015 |
|
RU2593342C1 |
METHOD FOR COMBINED TREATMENT OF RESECTABLE LOCALLY ADVANCED GASTRIC CANCER WITH PERITONEAL CARCINOMATOSIS APPLYING PERSONALISED SYSTEMIC AND INTRAPERITONEAL CHEMOTHERAPY | 2021 |
|
RU2773100C1 |
METHOD FOR PERSONALIZED ASSIGNMENT OF NEOAJUVANT CHEMOTHERAPY TO PATIENTS SUFFERING FROM LUMINAL TYPE B BREAST CANCER | 2015 |
|
RU2594251C1 |
METHOD OF COMBINED TREATMENT OF NON-SMALL CELL LUNG CANCER OF II AND III STAGE | 2011 |
|
RU2455986C1 |
METHOD OF EVALUATION OF SENSITIVITY OF LUNG CANCER CELLS TO DOXORUBICIN BASED ON EXPRESSION LEVELS OF MARKER GENES AND SET FOR ITS IMPLEMENTATION | 2013 |
|
RU2528247C2 |
METHOD OF TREATING BREAST CANCER WITH COMPOUND OF 4-IODINE-3-NITROBENZAMINE IN COMBINATION WITH ANTICANCER AGENTS | 2008 |
|
RU2480211C2 |
METHOD FOR COMBINATION THERAPY OF STAGE II AND III NON-SMALL CELL LUNG CANCER WITH PRE- AND POSTOPERATIVE CHEMOTHERAPY | 2011 |
|
RU2492855C2 |
METHOD FOR PREDICTING THE OUTCOME OF OVARIAN CANCER FOLLOWING ADJUVANT CHEMOTHERAPY ACCORDING TO THE AP | 2018 |
|
RU2699561C1 |
Authors
Dates
2018-08-28—Published
2017-04-12—Filed